FDA OrangeBook code

U-1211

USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA